Indivior (OTCMKTS:INVVY – Get Free Report) and NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Volatility and Risk
Indivior has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Profitability
This table compares Indivior and NovaBay Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Indivior | N/A | N/A | N/A |
NovaBay Pharmaceuticals | -91.86% | -744.33% | -106.89% |
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Indivior | 0 | 0 | 0 | 0 | N/A |
NovaBay Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Earnings and Valuation
This table compares Indivior and NovaBay Pharmaceuticals”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Indivior | $791.00 million | 3.81 | $205.00 million | $1.05 | 20.81 |
NovaBay Pharmaceuticals | $13.88 million | 0.06 | -$9.64 million | ($109.09) | -0.01 |
Indivior has higher revenue and earnings than NovaBay Pharmaceuticals. NovaBay Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
0.1% of Indivior shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Indivior beats NovaBay Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Indivior
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.